
Review invitation: Association Between Glycated Hemoglobin and Lipid...

1 message

Frontiers in Medicine Editorial Office <medicine.editorial.office@frontiersin.org>

Tue, Mar 31, 2026 at
12:48 AM

Reply-To: Frontiers in Medicine Editorial Office <medicine.editorial.office@frontiersin.org>

To: yennyfarmako@trisakti.ac.id

Dear Dr Yenny Yenny,

You're invited to review the manuscript "Association Between Glycated Hemoglobin and Lipid Parameters at the Time of Type 2 Diabetes Mellitus Diagnosis: Evidence From a Regional Cohort", submitted to Frontiers in Medicine, section Family Medicine and Primary Care.

You'll find the abstract and key manuscript details at the end of this message. If you're available, please let us know using the link below:

[Accept invitation](#)

Need more time? Once you accept, you can request an extension in the Review Forum (or email us directly by replying to this email).

If you're unavailable or the topic isn't within your scope, let us know here:

[Decline invitation](#)

Why take part?

Peer review works best when everyone contributes. By supporting it, you help ensure that when your own research is under review, it receives the same fairness and timeliness. Your insights not only raise the quality of published work but also give you early access to cutting-edge research in your field.

Thank you for letting us know your preference either way.

With best regards,

Frontiers in Medicine Editorial Office
Editorial Office, Frontiers in Medicine
<https://www.frontiersin.org/>

-----MANUSCRIPT DETAILS-----

Journal: Frontiers in Medicine, section Family Medicine and Primary Care

Manuscript title: Association Between Glycated Hemoglobin and Lipid Parameters at the Time of Type 2 Diabetes Mellitus Diagnosis: Evidence From a Regional Cohort

Manuscript ID: 1833588

Edited by: Ambar Kulshreshtha

Abstract: Type 2 diabetes mellitus (T2DM) is associated with lipid abnormalities that increase cardiovascular risk; however, evidence regarding this relationship at diagnosis is limited. This study aimed to examine the association between glycated hemoglobin (HbA1c) and lipid parameters at the time of T2DM diagnosis. A retrospective cross-sectional study included 3,501 newly diagnosed T2DM patients treated within the Riojano Health Service between 2019 and 2025. Spearman correlations and linear regression were used to assess associations between HbA1c and lipid parameters. The study was approved by the Research Ethics Committee of La Rioja (CEImLAR, PI 778). HbA1c was positively correlated with total cholesterol (TC) ($\rho = 0.043$; $p < 0.05$), low-density lipoprotein cholesterol (LDL-C) ($\rho = 0.044$; $p < 0.05$) and triglycerides (TG) ($\rho = 0.217$; $p < 0.001$), and inversely correlated with high-density lipoprotein cholesterol (HDL-C) ($\rho = -0.213$; $p < 0.001$). In linear regression adjusted for age, sex, and body mass index (BMI), higher HbA1c was associated with increased TC, TG and decreased HDL-C. These findings highlight that at diagnosis, higher HbA1c levels are associated with a more atherogenic lipid profile, emphasizing the importance of early metabolic assessment and comprehensive cardiovascular risk management, with an essential role for nursing in

early intervention, patient education and prevention.

If you encounter any technical issue, contact support@frontiersin.org, with AJWdno7o2w11L6W as reference.
[Unsubscribe](#) | [Email Preferences](#)

Dear Dr Yenny,

Thank you for agreeing to review the manuscript “**Association Between Glycated Hemoglobin and Lipid Parameters at the Time of Type 2 Diabetes Mellitus Diagnosis: Evidence From a Regional Cohort**”.

What's next?

You can access the manuscript and complete your structured review report via the link below:

Access your review

If the button doesn't work, copy and paste this link into your browser:

<https://review.frontiersin.org/review/bootstrap/00cbc252-44c6-4a32-8e42-d6ee17bb3799>

Submitting your review report promptly allows the authors to revise their manuscript sooner. A review certificate will be issued to you in MyFrontiers after a final decision of accept or reject has been taken on the manuscript. 88% of reviewers submit their assessment within 10 days of accepting the invitation. If you require more time, you can request an extension of your deadline directly through the Review Forum.

As a reminder, reviewers remain anonymous throughout the process. Please maintain this confidentiality when interacting with fellow reviewers. You can learn more about the review process in our guidelines.

You can contact the handling editor or the editorial office at any point with any questions. For a fast response, use the chatbot on the Review Forum.

Best regards,
Your Frontiers in Medicine team

Frontiers | Editorial Office - Collaborative Peer Review Team
www.frontiersin.org
Avenue du Tribunal Fédéral 34
1005 Lausanne Switzerland

For technical issues please contact our IT Helpdesk (support@frontiersin.org) or visit our Frontiers Help Center (helpcenter.frontiersin.org)

MANUSCRIPT DETAILS

Journal:	Frontiers in Medicine, section Family Medicine and Primary Care
Manuscript title:	Association Between Glycated Hemoglobin and Lipid Parameters at the Time of Type 2 Diabetes Mellitus Diagnosis: Evidence From a Regional Cohort
Manuscript ID:	1833588
Authors:	Raquel Sainz-Prado, Beatriz Rodríguez-Roca, Miren Idoia Pardavila-Belio, Paula Rojas-García, Félix Rivera-Sanz and Elena Andrade-Gómez
Edited by:	Ambar Kulshreshtha

If you encounter any technical issue, contact support@frontiersin.org, with HL9VYChoBO7uBQW as reference.

Association Between Glycated Hemoglobin and Lipid Parameters at the Time of Type 2 Diabetes Mellitus Diagnosis: Evidence From a Regional Cohort

Raquel Sainz-Prado^{1, 2}, Beatriz Rodríguez-Roca^{3, 4*}, Miren Idoia Pardavila-Belio^{5, 6}, Paula Rojas-García⁷, Félix Rivera-Sanz⁸, Elena Andrade-Gómez⁹

¹Department of Nursing, University of La Rioja, 26004, Logroño, La Rioja, Spain, ²Oncology Unit of Hospital San Pedro, La Rioja Health Service, 26006, Logroño, La Rioja, Spain, ³Department of Physiatry and Nursing, Faculty of Health Sciences, University of Zaragoza, C/Domingo Miral s/n, 50009, Zaragoza, Spain, ⁴SAPIENF (B53_23R) Research Group, Faculty of Health Sciences, University of Zaragoza, Zaragoza, Spain, ⁵School of Nursing, Community, Maternity and Pediatric Nursing, University of Navarra, Pamplona, Spain, ⁶IdiSNA, Navarra Institute for Health Research, Pamplona, Spain, ⁷Department of Economics and Business, University of La Rioja, La Rioja, Logroño, La Rioja, Spain, ⁸Data Science Unit, Fundación Rioja Salud, Logroño, La Rioja, Spain, ⁹Department of Nursing, University of La Rioja, 26004, Logroño, La Rioja, Spain

Submitted to Journal:

Frontiers in Medicine

Specialty Section:

Family Medicine and Primary Care

Article type:

Original Research Article

Manuscript ID:

1833588

Received on:

18 Mar 2026

Journal website link:

www.frontiersin.org

Scope Statement

Type 2 diabetes mellitus (T2DM) is strongly associated with cardiovascular disease, yet evidence on the relationship between glycemic control and lipid profile at the time of diagnosis remains limited. This study provides evidence from a large regional cohort of newly diagnosed T2DM patients, examining the association between glycosylated hemoglobin (HbA1c) and lipid parameters at disease onset. Our findings show that higher HbA1c levels were independently associated with a more atherogenic lipid profile, characterized by increased total cholesterol and triglycerides and reduced HDL cholesterol. These results suggest that cardiovascular risk may already be present at the earliest stages of T2DM and underscore the importance of early, comprehensive metabolic assessment. By identifying HbA1c as a marker linked to adverse lipid patterns at diagnosis, the study supports integrated and individualized management strategies addressing both glycemic control and cardiovascular risk from the outset. This evidence is particularly relevant to clinical practice, contributing to improved early risk stratification and preventive care in patients with T2DM, and aligns with the aims of Frontiers in Medicine.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Credit Author Statement

Beatriz Rodríguez-Roca: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. **Elena Andrade-Gómez:** Conceptualization, Methodology, Supervision, Visualization, Writing – original draft, Writing – review & editing. **Félix Rivera-Sanz:** Resources, Validation, Writing – review & editing. **Miren Idoia Pardavila-Belio:** Formal Analysis, Validation, Writing – review & editing. **Paula Rojas-García:** Data curation, Validation, Writing – review & editing. **Raquel Sainz-Prado:** Conceptualization, Data curation, Formal Analysis, Methodology, Visualization, Writing – original draft, Writing – review & editing.

Keywords

clinical practice, Fasting plasma glucose, Glycosylated hemoglobin, lipid profile, Nursing, Total cholesterol, Type 2 diabetes mellitus

Abstract

Word count: 200

Type 2 diabetes mellitus (T2DM) is associated with lipid abnormalities that increase cardiovascular risk; however, evidence regarding this relationship at diagnosis is limited. This study aimed to examine the association between glycosylated hemoglobin (HbA1c) and lipid parameters at the time of T2DM diagnosis. A retrospective cross-sectional study included 3,501 newly diagnosed T2DM patients treated within the Riojano Health Service between 2019 and 2025. Spearman correlations and linear regression were used to assess associations between HbA1c and lipid parameters. The study was approved by the Research Ethics Committee of La Rioja (CEImLAR, PI 778). HbA1c was positively correlated with total cholesterol (TC) ($\rho = 0.043$; $p < 0.05$), low-density lipoprotein cholesterol (LDL-C) ($\rho = 0.044$; $p < 0.05$) and triglycerides (TG) ($\rho = 0.217$; $p < 0.001$), and inversely correlated with high-density lipoprotein cholesterol (HDL-C) ($\rho = -0.213$; $p < 0.001$). In linear regression adjusted for age, sex, and body mass index (BMI), higher HbA1c was associated with increased TC, TG and decreased HDL-C. These findings highlight that at diagnosis, higher HbA1c levels are associated with a more atherogenic lipid profile, emphasizing the importance of early metabolic assessment and comprehensive cardiovascular risk management, with an essential role for nursing in early intervention, patient education and prevention.

Funding statement

The author(s) declare that no financial support was received for the research and/or publication of this article.

Ethics statements

Studies involving animal subjects

Generated Statement: No animal studies are presented in this manuscript.

Studies involving human subjects

Generated Statement: The studies involving humans were approved by Research Ethics Committee of La Rioja (CEImLAR). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin because Due to the retrospective nature of the study and the use of fully anonymized data.

Inclusion of identifiable human data

Generated Statement: No potentially identifiable images or data are presented in this study.

Data availability statement

Generated Statement: The data analyzed in this study is subject to the following licenses/restrictions: **The data supporting the findings of this study are available from the corresponding author upon reasonable request. Access to the data will be granted subject to appropriate justification and compliance with relevant ethical and legal requirements.** Requests to access these datasets should be directed to brodriguez@unizar.es.

Generative AI disclosure

No Generative AI was used in the preparation of this manuscript.

In review

Association Between Glycated Hemoglobin and Lipid Parameters at the Time of Type 2 Diabetes Mellitus Diagnosis: Evidence From a Regional Cohort

1 Raquel Sainz-Prado^{1,2}, Beatriz Rodríguez-Roca^{3,4*}, Miren Idoia Pardavila-Belio^{5,6}, Paula Rojas-
2 García⁷, Félix Rivera-Sanz⁸, Elena Andrade-Gómez¹

3 ¹ Department of Nursing, University of La Rioja, 26004, Logroño, La Rioja, Spain.
4 raquel.sainz@alum.unirioja.es, elena.andrade@unirioja.es

5 ² Oncology Unit of Hospital San Pedro, La Rioja Health Service, 26006, Logroño, La Rioja, Spain.

6 ³ Department of Physiatry and Nursing, Faculty of Health Sciences, University of Zaragoza,
7 C/Domingo Miral s/n, 50009 Zaragoza, Spain. brodriguez@unizar.es

8 ⁴ SAPIENF (B53_23R) Research Group, Faculty of Health Sciences, University of Zaragoza,
9 Zaragoza, Spain.

10 ⁵ School of Nursing, Community, Maternity and Pediatric Nursing, University of Navarra, Pamplona,
11 Spain. mpardavila@unav.es

12 ⁶ IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

13 ⁷ Department of Economics and Business, University of La Rioja, La Rioja, Logroño, Spain.
14 paula.rojas@unirioja.es

15 ⁸ Data Science Unit, Fundación Rioja Salud, Logroño, La Rioja, Spain. frivera@riojasalud.es

16 * Correspondence:

17 Corresponding Author

18 brodriguez@unizar.es

19 **Keywords.** Glycated hemoglobin, fasting plasma glucose, lipid profile, total cholesterol, type 2
20 diabetes mellitus, nursing, clinical practice.

21 Word count. 2,927; Figures: 1; Tables: 4.

22 Abstract

23 **Background and Objectives.** Type 2 diabetes mellitus (T2DM) is associated with lipid abnormalities
24 that increase cardiovascular risk; however, evidence regarding this relationship at diagnosis is limited.
25 This study aimed to examine the association between glycated hemoglobin (HbA1c) and lipid
26 parameters at the time of T2DM diagnosis.

27 **Methods.** A retrospective cross-sectional study included 3,501 newly diagnosed T2DM patients
28 treated within the Riojano Health Service between 2019 and 2025. Spearman correlations and linear
29 regression were used to assess associations between HbA1c and lipid parameters. The study was
30 approved by the Research Ethics Committee of La Rioja (CEImLAR, PI 778).

31 **Results.** HbA1c was positively correlated with total cholesterol (TC) ($\rho = 0.043$; $p < 0.05$), low-density
32 lipoprotein cholesterol (LDL-C) ($\rho = 0.044$; $p < 0.05$) and triglycerides (TG) ($\rho = 0.217$; $p < 0.001$), and
33 inversely correlated with high-density lipoprotein cholesterol (HDL-C) ($\rho = -0.213$; $p < 0.001$). In linear
34 regression adjusted for age, sex, and body mass index (BMI), higher HbA1c was associated with
35 increased TC, TG and decreased HDL-C.

36 **Conclusion.** At diagnosis, higher HbA1c levels were associated with a more atherogenic lipid
37 profile—higher TC and TG, and lower HDL-C—highlighting the importance of early metabolic
38 assessment and comprehensive cardiovascular risk management, with an essential role for nursing in
39 early intervention, patient education and prevention.

40 1 Introduction

41 Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by chronic hyperglycemia
42 resulting from impaired insulin secretion, impaired insulin action, or both (1). It is one of the most
43 prevalent chronic diseases worldwide, currently affecting more than 463 million people, with
44 projections estimating that this number will exceed 690 million by 2045 (2).

45 Individuals with T2DM present a two- to fourfold higher risk of cardiovascular disease (CVD)
46 compared with general population, positioning CVD as the principal cause of morbidity and mortality
47 in this group (3) and a major public health burden worldwide. From a population health perspective,
48 inadequate glycemic control represents a key modifiable determinant of CVD risk, with glycated
49 hemoglobin (HbA1c) functioning as a standardized epidemiological indicator of long-term
50 hyperglycemia over the preceding 2–3 months and demonstrating a robust and consistent association
51 with cardiovascular outcomes (4,5).

52 Sustained hyperglycemia contributes to CVD through multiple pathophysiological mechanisms,
53 including insulin resistance, low-grade chronic inflammation, endothelial dysfunction, and
54 microvascular damage mediated by advanced glycation end-products (6,7). From a public health
55 perspective, these mechanisms underpin the high population-attributable risk of cardiovascular
56 complications associated with T2DM, especially when hyperglycemia remains undetected or poorly
57 controlled. T2DM commonly coexists with other metabolic disturbances such as dyslipidemia and
58 hypertension, which cluster at the population level and synergistically amplify cardiometabolic risk
59 (2).

60 The characteristic dyslipidemia of T2DM includes elevated triglycerides (TG), increased small dense
61 LDL particles, and reduced HDL cholesterol (HDL-C), forming a highly atherogenic profile (8,9).
62 These lipid abnormalities are highly prevalent in real-world clinical populations and represent a key
63 target for early cardiovascular risk reduction strategies. Hyperglycemia and insulin resistance modify
64 lipid metabolism and promote the accumulation of atherogenic lipoproteins, contributing to the early
65 development of subclinical atherosclerosis (10).

66 The role of nursing is essential in early detection, comprehensive assessment, and initial management
67 of patients with T2DM, particularly at the time of diagnosis when metabolic alterations may go
68 unnoticed (11). From a clinical perspective, nursing professionals play a key role in screening,
69 surveillance a longitudinal monitoring glycemic and lipid parameters, identifying cardiovascular risk
70 factors, and providing therapeutic education aimed at enhancing adherence to both pharmacological
71 and non-pharmacological treatments (12,13). Evidence shows that nurse-led self-management
72 education programs are effective in improving glycemic control and even lipid-related outcomes,
73 underscoring the importance of nursing involvement in metabolic risk reduction (13). In addition,

74 nursing contributes substantially to the promotion of healthy lifestyles -including healthy eating,
75 physical activity, and self-care behaviors- which are essential for improving metabolic control and
76 reducing the progression toward an atherogenic lipid profile (14). Due to their continuous close contact
77 with patients and their ability to deliver individualized interventions, nurses are strategically positioned
78 to implement early preventive measures and support an integrated and effective management of T2DM
79 from the very beginning of the diagnostic process (11,14,15).

80 Despite the high prevalence of T2DM and its strong association with CVD, evidence from our context
81 is limited regarding the metabolic profile of newly diagnosed patients, particularly the relationship
82 between early glycemic control and lipid alterations. Understanding this interaction at the initial stages
83 of the disease trajectory is crucial for informing therapeutic strategies and reducing future
84 cardiovascular risk.

85 Therefore, this study aimed to explore the relationship between HbA1c levels and lipid parameters in
86 a retrospective cohort of newly diagnosed T2DM patients, providing evidence to support early,
87 prevention-oriented clinical decision making at the time of diagnosis.

88 **2 Methods**

89 **2.1 Study Design**

90 A retrospective cross-sectional study was conducted using routinely collected clinical and biochemical
91 data from patients newly diagnosed with type 2 diabetes mellitus (T2DM). Baseline information
92 corresponding to the time of diagnosis was obtained from electronic medical records of the Riojano
93 Health Service (Servicio Riojano de Salud, SERIS). The study included diagnoses recorded between
94 2019 and 2025.

95 **2.2 Population**

96 The study included 3,501 individuals with a diagnosis of T2DM registered in SERIS. Eligible
97 participants were identified using the International Classification Diseases, 10th revision (ICD-10)
98 Code E11. The final sample size was determined by the availability of medical records meeting the
99 predefined inclusion and exclusion criteria during the study period.

100 **2.3 Inclusion criteria**

- 101 • Residence in the Autonomous Community of La Rioja.
- 102 • Diagnosis of T2DM based on ICD-10 code E11, confirmed by at least one of the following
103 criteria:
 - 104 o HbA1c \geq 6.5% (48 mmol/mol) in two separate tests
 - 105 o Fasting plasma glucose \geq 126 mg/dL in two separate tests
- 106 • Age \geq 18 years

107 **2.4 Exclusion criteria (ICD-10)**

- 108 • Pregnancy
- 109 • Ongoing cancer treatment
- 110 • Alzheimer's disease, dementia, or severe cognitive impairment
- 111 • Heart failure (New York Heart Association (NYHA) class III–IV)
- 112 • Left ventricular ejection fraction (LVEF) $<$ 40%
- 113 • Severe functional limitations due to peripheral arterial disease

114 **2.5 Data sources and data collection**

115 Data were extracted from electronic medical record by the Data Science, Big Data and Artificial
116 Intelligence Unit (UCIDA) of SERIS Information between 2019 and 2025.

117 Study variables

118 All sociodemographic, clinical, and biochemical variables were obtained from patients' medical
119 records.

120 Sociodemographic variables:

121 Sex, date of birth, age, city and country of origin, rural/urban residence, primary care center, health
122 district, and history of anxiety or depression.

123 Clinical variables:

124 Date of diabetes diagnosis, body mass index (BMI; kg/m²), systolic blood pressure (SBP), and diastolic
125 blood pressure (DBP). Clinical measurements were collected from forms within a maximum of 60 days
126 from the diagnosis date.

127 Biochemical variables:

128 Glucose, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein
129 cholesterol (HDL-C), triglycerides (TG) and glycated hemoglobin (HbA1c). Biochemical variables
130 corresponded to the laboratory test closest to the diagnosis date, within a maximum window of 60 days.

131 **2.6 Ethical Considerations**

132 The study was conducted in accordance with the principles of the Declaration of Helsinki and
133 applicable national and institutional regulations on human subject research. Informed consent from
134 patients was not required, as only fully anonymized data from medical records were used.

135 Data were provided by the Data Science, Big Data, and Artificial Intelligence Unit (UCIDA) of the
136 public health system of La Rioja, within the framework of a project approved by the Research Ethics
137 Committee of La Rioja (CEImLAR, PI 778, September 2025). Patient data were coded and handled in
138 compliance with current legislation on data protection and used exclusively for research purposes.

139 **2.7 Statistical Analysis**

140 Statistical analyses were conducted using IBM SPSS Statistics version 28.01.1 (16). Qualitative
141 variables were described as frequencies and percentages (n, %); quantitative variables were
142 summarized as mean \pm standard deviation (SD).

143 The distribution of continuous variables was evaluated using graphical methods and tests of normality.
144 Differences in lipid parameters across clinically relevant HbA1c categories were assessed using one-
145 way analysis of variance (ANOVA) for TC, LDL-C, and HDL-C, and the Kruskal–Wallis test for TG.

146 Associations between HbA1c and lipid parameters were initially explored using Spearman correlation
147 coefficients. To account for potential confounding, multiple linear regression models were performed

148 using HbA1c as the main predictor of lipid profile variables, adjusting for age, sex, and BMI. Statistical
149 significance was set at $p < 0.05$, with a 95% confidence level.

150 **3 Results**

151 A total of 3,504 patients were initially identified. Three patients were excluded due to missing
152 laboratory data, resulting in a final sample of 3,501 patients included in the analysis (Fig. 1).

153 Of the 3,501 patients included, not all laboratory parameters were available for every participant.
154 Additionally, extreme or implausible values were excluded from the analyses to minimize potential
155 errors. Therefore, the number of participants with available data for each biochemical variable varied.

156 Fig. 1. Flow diagram of participant selection for the cross-sectional analysis.

157 **3.1 General characteristics**

158 The study included 3,501 patients with a mean age of 67.9 ± 12.94 years; 56.2% were men and 43.8%
159 were women. The majority (84.6%) were from Spain, whereas 15.4% were from other countries. Most
160 patients (67%) lived in urban areas, while 33% resided in rural settings (Table 1).

161 Table 1. Sociodemographic characteristics (n = 3,501).

162 Regarding the distribution of diagnoses over time, 15.1% of patients were diagnosed with T2DM in
163 2019, 14.3% in 2020, 15.9% in 2021, 17.8% in 2022, and 17.1% in 2023. A marked decrease was
164 observed in 2024, which persisted into 2025, with 9.9% of diagnoses occurring in each year.

165 **3.2. Clinical and biochemical parameters**

166 Table 2 presents the mean values, standard deviations, and number of valid observations for the main
167 clinical and biochemical variables, including glucose, HbA1c, lipid profile, BMI, and blood pressure,
168 stratified by sex and for the total population.

169 Table 2. Clinical and biochemical parameters in men, women, and the total population.

170 Among the 2,903 patients with available HbA1c at diagnosis, 26.4% had values between 7.0% (53
171 mmol/mol) and 8.9% (74 mmol/mol), and 12.4% had HbA1c $\geq 9\%$ (75 mmol/mol). TG data were
172 available for 1,508 patients at diagnosis. Among these, 668 patients (44.3%) had TG levels between
173 150 and 200 mg/dL and 840 patients (55.7%) had values >200 mg/dL.

174 **3.3. Lipid profile according to HbA1c categories**

175 When lipid parameters were analyzed according to clinically relevant HbA1c categories (Table 3), a
176 progressive worsening of the lipid profile was observed with increasing HbA1c levels. Higher HbA1c
177 categories were associated with higher TC, LDL-C and TG levels, together with lower HDL-C values.
178 These differences remained statistically significant across HbA1c groups for TC, HDL-C and TG.

179 Table 3. Lipid profile according to clinically relevant HbA1c categories.

180 3.4. Correlation and regression analysis

181 Spearman correlation analyses showed a statistically significant but weak positive association between
182 HbA1c and TC ($\rho = 0.043$; $p < 0.05$), LDL-C ($\rho = 0.044$; $p < 0.05$) and TG ($\rho = 0.217$; $p < 0.001$), as
183 well as a negative association with HDL-C ($\rho = -0.213$; $p < 0.001$).

184 Given the generally weak correlations observed, multiple linear regression analyses adjusted for age,
185 sex, and BMI were performed. HbA1c was independently associated with higher TC and TG levels, as
186 well as a lower HDL-C (all $p < 0.001$), whereas its association with LDL-C did not reach statistical
187 significance.

188 Sex consistently demonstrated an influence across models, with women presenting higher TC, LDL-C
189 and HDL-C levels compared with men. Age was negatively associated with TC, LDL-C and TG, while
190 BMI showed a significant inverse association with HDL-C and a positive association with TG.

191 These findings indicate that, at the biochemical evaluation performed at the time of T2DM diagnosis,
192 higher HbA1c levels are independently associated with lipid parameters, after adjustment for age, sex
193 and BMI (Table 4).

194 Table 4. Effect of HbA1c, sex, age, and BMI on lipid parameters: Adjusted multiple linear regression
195 results.

196 4 Discussion

197 This study examined the relationship between glycemic control and lipid profile in a cohort of 3,504
198 patients newly diagnosed with T2DM. The mean age of the cohort was 67.9 years, a factor closely
199 linked to the incidence of diabetes and its complications, likely related to reduced physical activity and
200 certain lifestyle habits (17,18). The higher prevalence of diabetes in men (56.2%) differs from what
201 has been reported in other population contexts (19,20). A rise in the number of T2DM diagnoses was
202 observed in the years immediately following the COVID-19 pandemic, likely related to lifestyle
203 changes during lockdown including reduced physical activity, poorer dietary habits, increased
204 consumption of alcohol and tobacco, and sleep disturbances, stress, anxiety, and depression (21-23).
205 These factors may have contributed to increases in overweight, obesity, and metabolic disorders (24)
206 in addition to potential metabolic alterations derived from COVID-19 infection itself (25-28).

207 Although the association between diabetes mellitus and cardiovascular risk is well established (29,30),
208 the main findings of this study indicate that this relationship is present from the early stages of the
209 disease. Even at the time of diagnosis, poorer glycemic control—reflected by higher HbA1c levels—
210 was independently associated with a more atherogenic lipid profile, characterized by higher total TC
211 and TG, and lower HDL-C levels, consistent with previous studies (31). Specifically, after adjustment
212 for age, sex and BMI, each 1% increase in HbA1c (≈ 11 mmol/mol) was associated with an increase of
213 4.25 mg/dL in TC, 15.65 mg/dL in TG, and a decrease of 1.40 mg/dL in HDL-C, reinforcing evidence
214 that chronic hyperglycemia disrupts lipid metabolism and contributes to cardiovascular risk even
215 before clinical complications become apparent.

216 Sex also had a significant influence on the lipid profile: after adjustment, women presented slightly
217 higher TC, LDL-C and HDL-C levels, in line with previous reports (32,33). This may be related to
218 decreased estrogen levels after menopause, which have been associated with increases in TC and LDL-
219 C (34).

220 The absence of a significant association between HbA1c and LDL-C concentration in the adjusted
221 models does not preclude the presence of atherogenic lipid alterations. In T2DM, dyslipidemia is
222 characterized by elevated TG, reduced HDL-C, and a predominance of small dense LDL particles,
223 while total LDL-C concentrations often remain within normal ranges (35,36). Previous studies have
224 similarly reported that HbA1c is not significantly associated with LDL-C levels (37), whereas others
225 have found positive correlations (38-40); however, these studies differ substantially from ours in terms
226 of geographical and ethnic context, sample size and population characteristics.

227 Hypertriglyceridemia, in particular, was closely linked to poor glycemic control, reflecting the severity
228 of insulin resistance and hepatic lipid overproduction (36). This can be explained by the
229 pathophysiology of T2DM: insulin facilitates glucose uptake and suppresses lipolysis in adipose tissue
230 (41). However, in the presence of insulin resistance or deficiency, this response is impaired, increasing
231 the release of free fatty acids and glycerol into circulation. These substrates are subsequently
232 transported to the liver, where they promote hepatic synthesis of phospholipids, cholesterol, and TG,
233 resulting in increased very-low-density lipoprotein (VLDL) production and elevated circulating TG
234 levels (42,43). Consistent with this mechanism, our findings show that TG levels increase progressively
235 as HbA1c rises, indicating that hypertriglyceridemia develops early in T2DM and contributes to the
236 atherogenic lipid profile from the disease onset.

237 From a clinical practice perspective, these findings reinforce the crucial role of healthcare professionals
238 in the early identification and management of metabolic alterations in newly diagnosed T2DM patients,
239 with nurse-led care shown to improve cardiovascular risk profiles and early metabolic detection
240 (11,15). Given that higher HbA1c levels were associated with a more atherogenic lipid profile, nursing
241 professionals are positioned to play a proactive role in cardiovascular risk stratification, patient
242 education, and the implementation of individualized care plans, consistent with evidence showing
243 superior glycemic control under nurse-led follow-up when compared to conventional care (12,13).
244 Their participation in structured follow-up, motivational interviewing, and lifestyle counseling is
245 essential to promote adherence and prevent worsening of dyslipidemia and hyperglycemia, and effect
246 aligned with meta-analytic data demonstrating that nurse-led self-management education substantially
247 improves metabolic outcomes (13,14). Furthermore, interventions delivered by nurses that focus on
248 lifestyle modification, including guidance on healthy eating patterns, increased physical activity, and
249 effective self-care practices, play a decisive role in strengthening diabetes self-management and have
250 been shown to positively influence long-term metabolic control (14,15). Taken collectively, these
251 findings highlight the strategic position of nurses in ensuring continuity of care, promoting early
252 preventive measures, and facilitating integrated management from diagnosis onward.

253 The findings of this study have important clinical implications. The positive relationship between
254 HbA1c and lipid profile in newly diagnosed T2DM suggests that HbA1c may serve as a biomarker not
255 only for glycemic control but also for early cardiovascular risk detection. Elevated HbA1c levels,
256 indicating insufficient glucose regulation, may help identify patients who are more likely to present
257 lipid abnormalities. This underscores the need for early implementation of integrated therapeutic
258 strategies—targeted lipid control and lifestyle interventions—that simultaneously address glucose and
259 lipid metabolism to reduce cardiovascular risk. Collectively, these results contribute meaningful
260 evidence on the relationship between glycemic and lipid parameters in the population of La Rioja.

261 This study has some limitations that should be considered when interpreting the results. First, due to
262 the cross-sectional design, the findings reflect associations at a single point in time, preventing causal
263 inferences or temporal sequencing between the variables. Second, biochemical and clinical parameters
264 may have been influenced by unmeasured confounders, such as dietary patterns, intense physical

265 activity, stress levels, acute illness, or use of medications that could modify metabolic outcomes. Third,
266 certain biochemical markers, such as TG, may exhibit temporal variability, and reliance on a single
267 measurement could introduce information bias and limit estimation precision. Fourth, the number of
268 observations varied across clinical and biochemical parameters due to incomplete laboratory data,
269 which may affect the precision of estimates and comparisons between groups. These limitations
270 highlight the need for caution when interpreting results and suggest that longitudinal research or
271 repeated-measure studies are warranted to confirm and expand upon these associations.

272 Despite the inherent limitations of cross-sectional designs, this study benefits from a large, community-
273 based cohort of adults aged 20 to 102 years. The substantial sample size and strong representativeness
274 enhance external validity and provide a robust and generalizable depiction of the sociodemographic
275 and clinical characteristics of this population. While causality cannot be established, cross-sectional
276 designs offer valuable insights into the distribution and prevalence of early metabolic alterations and
277 serve as a solid foundation for generating hypotheses and informing future longitudinal or experimental
278 research.

279 **5 Conclusion**

280 The findings of this study indicate that, in this predominantly older adult population of mostly Spanish
281 origin, the lipid profile is significantly influenced by glycemic control, as well as by sex and age.
282 HbA1c was positively associated with TC and TG, and negatively associated with HDL, while no
283 significant association was observed with LDL-C. These results reinforce the importance of achieving
284 adequate glycemic control to reduce cardiovascular risk.

285 In addition to these findings, the present study highlights the essential role of healthcare professionals
286 in translating early metabolic assessment into effective clinical action. Nurses are uniquely positioned
287 to integrate glycemic and lipid data into personalized care strategies, reinforce treatment adherence,
288 and guide patients in adopting sustainable lifestyle modifications that reduce cardiovascular risk. Their
289 continuous and multidisciplinary involvement ensures that individuals newly diagnosed with T2DM
290 receive timely education, monitoring, and support, thereby enhancing the impact of early interventions
291 on long-term health outcomes. Incorporating nursing-led approaches into initial diabetes management
292 may therefore strengthen preventive efforts and improve the overall quality of care.

293 From a clinical perspective, these results highlight the need for early and comprehensive cardiovascular
294 risk assessment in patients with newly diagnosed T2DM—one that integrates both glycemic control
295 and detailed lipid profiling. Early identification of unfavorable lipid patterns would allow the
296 implementation of timely preventive and therapeutic strategies aimed at reducing cardiovascular risk
297 and improving overall disease management. This underscores the relevance of personalized, risk-based
298 approaches to care in T2DM.

299 **6 Abbreviations**

300 BMI: body mass index
301 CVD: cardiovascular disease
302 HDL-C: high-density lipoprotein cholesterol
303 HbA1c: glycated hemoglobin
304 LDL-C: low-density lipoprotein cholesterol
305 SD: standard deviation
306 TC: total cholesterol
307 TG: triglycerides

308 T2DM: type 2 diabetes mellitus

309 **7 Author Contributions**

310 RS-P: Conceptualization, Methodology, Data curation, Formal analysis, Visualization, Writing –
311 original draft, Writing – review & editing. BR-R: Conceptualization, Supervision, Writing – original
312 draft, Writing – review & editing. MI P-B: Formal analysis, Validation, Writing – review & editing.
313 PR-G: Data curation, Validation, Writing – review & editing. FR-S: Resources, Validation, Writing –
314 review & editing. EA-G: Conceptualization, Methodology, Visualization, Supervision, Writing –
315 original draft, Writing – review & editing.

316 **8 Funding**

317 This research received no specific grant from any funding agency in the public, commercial, or not-
318 for-profit sectors.

319 **9 Acknowledgments**

320 Not applicable.

321 **10 References**

- 322 (1) Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. *Diabetes Care*.
323 (2025) 48:S27–49.
- 324 (2) IDF Diabetes Atlas. 9th edition. International Diabetes Federation (2019).
- 325 (3) ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. *Rev Esp Cardiol*. (2022)
326 75:364–369.
- 327 (4) Eslamian M, Mohammadinejad P, Aria Z, Nakhjavani M, Esteghamati A. Positive correlation of
328 serum adiponectin with lipid profile in patients with type 2 diabetes mellitus is affected by metabolic
329 syndrome status. *Arch Iran Med*.2016;19:269–274.
- 330 (5) Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, et al. Diabetes mellitus–related all-
331 cause and cardiovascular mortality in a national cohort of adults. *J Am Heart Assoc*. (2019) 8:e011295.
332 doi: 10.1161/JAHA.118.011295
- 333 (6) Fernández-Real JM. Insulin resistance and atherosclerosis: Impact of oxidative stress on endothelial
334 function. *Rev Esp Cardiol Supl*. (2008) 8:45–52.
- 335 (7) Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin
336 resistance and the development of cardiovascular disease. *Cardiovasc Diabetol*. (2018) 17:122. doi:
337 10.1186/s12933-018-0762-4
- 338 (8) Pedro-Botet J, Benaiges D, Pedragosa A. Diabetic dyslipidemia, macroangiopathy, and
339 microangiopathy. *Clin Investig Arterioscler*. (2012) 24:299–305. doi: 0.1016/j.arteri.2012.09.005
- 340 (9) Carmena R. High risk of lipoprotein dysfunction in type 2 diabetes mellitus. *Rev Esp Cardiol Supl*.
341 (2008) 8:19–26. doi: 10.1016/S1131-3587(08)73551-9

- 342 (10) Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic
343 implications. *Diabetes Metab Syndr Obes.* (2020) 13:3611–3616. doi: 10.2147/DMSO.S275898
- 344 (11) Zhang J, Zheng X, Ma D, Liu C, Ding Y. Nurse-led care versus usual care on cardiovascular risk
345 factors for patients with type 2 diabetes: a systematic review and meta-analysis. *BMJ Open.* (2022)
346 12:e058533. doi: 10.1136/bmjopen-2021-058533
- 347 (12) Thakur K, Sharma SK, Kant R, Kalyani V. Glycemic Control in Adult Patients With Type 2
348 Diabetes Mellitus Receiving Care Through a Nurse-Led Diabetic Follow-Up Clinic Versus
349 Conventional Care: A Randomized Controlled Trial. *Cureus.* (2025) 25;17:e79659. doi:
350 10.7759/cureus.c215
- 351 (13) Sun J, Fan Z, Kou M, Wang X, Yue Z, Zhang M. Impact of nurse-led self-management education
352 on type 2 diabetes: a meta-analysis. *Front Public Health.* (2025) 11;13:1622988. doi:
353 10.3389/fpubh.2025.1622988
- 354 (14) Makhfudli M, Efendi F, Pradipta RO, Ismanto AY, Chong MC, Tonapa SI. Efficacy of Nurse-Led
355 Digitalized Diabetes Management Program for Community-Dwelling Patients With Type 2 Diabetes
356 Mellitus: A Systematic Review and Meta-Analysis. *J Nurs Scholarsh.* (2025) 57(5):713-727. doi:
357 10.1111/jnu.70022
- 358 (15) Dailah HG. The Influence of Nurse-Led Interventions on Diseases Management in Patients with
359 Diabetes Mellitus: A Narrative Review. *Healthcare (Basel).* (2024) 30;12(3):352. doi:
360 10.3390/healthcare12030352
- 361 (16) IBM Corp. (2021). IBM SPSS Statistics (Version 28.0.1.1) (Software). Armonk, NY.
- 362 (17) Schernthaner G, Schernthaner-Reiter MH. Diabetes in the older patient: Heterogeneity requires
363 individualized therapeutic strategies. *Diabetologia.* (2018) 61:1503–1516. doi: 10.1007/s00125-018-
364 4547-9
- 365 (18) Fazeli PK, Lee H, Steinhauser ML. Aging as a powerful risk factor for type 2 diabetes mellitus
366 independent of body mass index. *Gerontology.* (2020) 66:209–210. doi: 10.1159/000501745
- 367 (19) Gatimu SM, Milimo BW, Sebastian MS. Prevalence and determinants of diabetes among older
368 adults in Ghana. *BMC Public Health.* (2016) 16:1174. doi: 10.1186/s12889-016-3845-8
- 369 (20) Veghari G, Sedaghat M, Joshaghani H, Hoseini SA, Niknezad F, Angizeh A, et al. Association
370 between sociodemographic factors and diabetes mellitus in northern Iran: A population-based study.
371 *Int J Diabetes Mellit.* (2010) 2:154–157. doi:10.1016/j.ijdm.2010.09.001
- 372 (21) Balanzá-Martínez V, Kapczynski F, de Azevedo Cardoso T, Atienza-Carbonell B, Rosa AR, Mota
373 JC, et al. The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional
374 scale. *Rev Psiquiatr Salud Ment.* (2021) 14:16–26. doi: 10.1016/j.rpsm.2020.07.003
- 375 (22) Maestre A, Sospedra I, Martínez-Sanz JM, Gutierrez-Hervas A, Fernández-Saez J, Hurtado-
376 Sánchez JA, et al. Assessment of Spanish food consumption patterns during COVID-19 home
377 confinement. *Nutrients.* (2021) 13:4122. doi: 10.3390/nu13114122

- 378 (23) Ammar A, Brach M, Trabelsi K, Chtourou H, Boukhris O, Masmoudi L, et al. Effects of COVID-
379 19 home confinement on eating behavior and physical activity: Results of the ECLB-COVID19
380 international online survey. *Nutrients*. (2020) 12:1583. doi: 10.3390/nu12061583
- 381 (24) Kluge HHP, Wickramasinghe K, Rippin HL, Mendes R, Peters DH, Kontsevaya A, et al.
382 Prevention and control of non-communicable diseases in the COVID-19 response. *Lancet*. (2020)
383 395:1678–1680. doi: 10.1016/S0140-6736(20)31067-9
- 384 (25) González-Herazo MA, Silva-Muñoz DC, Guevara-Martinez PA, Lozada-Martinez ID. Post-
385 COVID-19 neurological syndrome: A fresh challenge in neurological management. *Neurol Neurochir*
386 *Pol*. (2021) 55:413–414. doi: 10.5603/PJNNS.a2021.0052
- 387 (26) Camargo-Martínez W, Lozada-Martínez I, Escobar-Collazos A, Navarro-Coronado A, Moscote-
388 Salazar L, Pacheco-Hernández A, et al. Post-COVID-19 neurological syndrome: Implications for
389 sequelae treatment. *J Clin Neurosci*. (2021) 88:219–225. doi: 10.1016/j.jocn.2021.04.001
- 390 (27) Raveendran AV, Misra A. Post-COVID-19 syndrome (“Long COVID”) and diabetes: Challenges
391 in diagnosis and management. *Diabetes Metab Syndr*. (2021) 15:102235.
392 <https://doi.org/10.1016/j.dsx.2021.102235>
- 393 (28) Accili D. Can COVID-19 cause diabetes? *Nat Metab*. (2021) 3:123–125. doi: 10.1038/s42255-
394 020-00339-7
- 395 (29) Junttila MJ, Kiviniemi AM, Lepojärvi ES, Tulppo M, Piira OP, Kenttä T, et al. Type 2 diabetes
396 and coronary artery disease: Preserved ejection fraction and sudden cardiac death. *Heart Rhythm*.
397 (2018) 15:1450–1456. doi: 10.1016/j.hrthm.2018.06.017
- 398 (30) Guamán C, Acosta W, Alvarez C, Hasbum B. Diabetes and cardiovascular disease. *Rev Urug*
399 *Cardiol*. (2021) 36:e36104. doi: 10.29277/cardio.36.1.4
- 400 (31) Luo B, Xu W, Ye D, Bai X, Wu M, Zhang C, et al. Association between glycated hemoglobin and
401 the lipid profile at the Central Yunnan Plateau: A retrospective study. *Diabetes Metab Syndr Obes*.
402 (2024) 17:2975–2981. doi: 10.2147/DMSO.S469368
- 403 (32) Naeem M, Khattak RM, Ur Rehman M, Khan MN. The role of glycated hemoglobin (HbA1c) and
404 serum lipid profile measurements to detect cardiovascular diseases in type 2 diabetic patients. *South*
405 *East Asia Journal Of Public Health*. (2015) 5:30–34. doi: 10.3329/seajph.v5i2.28310
- 406 (33) Ahmad Khan H. Clinical significance of HbA1c as a marker of circulating lipids in male and
407 female type 2 diabetic patients. *Acta Diabetol*. (2007) 44:193–200. doi: 10.1007/s00592-007-0003-x.
- 408 (34) Anto EO, Obirikorang C, Annani-Akollor ME, Adua E, Donkor S, Acheampong E, et al.
409 Evaluation of dyslipidemia using a lipid-profile algorithm in newly diagnosed type II diabetes mellitus
410 patients: A cross-sectional study at Dormaa Presbyterian Hospital, Ghana. *Medicina (Kaunas)*. (2019)
411 55:392. doi: 10.3390/medicina55070392
- 412 (35) Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. *Nat Clin Pract Endocrinol Metab*. (2009)
413 5:150-159. doi: 10.1038/ncpendmet1066

- 414 (36) Taskinen MR. Diabetic dyslipidemia. *Atheroscler Suppl.* (2002) 3:47-51. doi: 10.1016/s1567-
415 5688(01)00006-x
- 416 (37) Alzahrani SH, Baig M, Aashi MM, Al-Shaibi FK, Alqarni DA, Bakhamees WH. Association
417 between glycated hemoglobin (HbA1c) and the lipid profile in patients with type 2 diabetes mellitus at
418 a tertiary care hospital: a retrospective study. *Diabetes Metab Syndr Obes.* (2019) 12:1639-1644. doi:
419 10.2147/DMSO.S222271
- 420 (38) Lnu P, Lnu J, Banerjee A, Bansal A, Gogoi JB. Lipoprotein Ratios: Correlations With Glycated
421 Hemoglobin Among Type 2 Diabetes Mellitus Patients. *Cureus.* (2024) 5;16:e53665. doi:
422 10.7759/cureus.53665
- 423 (39) Hussain A, Ali I, Ijaz M, Rahim A. Correlation between hemoglobin A1c and serum lipid profile
424 in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. *Ther Adv*
425 *Endocrinol Metab.* (2017) 8:51-57. doi: 10.1177/2042018817692296
- 426 (40) Handayani D, Rahmawati R, Dominica D, Salsabila J, Hafidzah K, Wafiqah A. Correlation of
427 HbA1c and lipid profile levels in Type 2 Diabetes Mellitus Patients at M Yunus Hospital. *Jurnal Ilmu*
428 *Kesehatan.* (2023) 11:67-76. doi: 10.30650/jik.v11i1.3656
- 429 (41) Luo Z, Wang Y, Xue M, Xia F, Zhu L, Li Y, et al. Astragaloside IV ameliorates fat metabolism
430 in the liver of aging mice through mitochondrial activity modulation. *J Cell Mol Med.* (2021) 25:8863–
431 8876. doi: 10.1111/jcmm.70876
- 432 (42) Zhong X, Ke C, Cai Z, Wu H, Ye Y, Liang X, et al. LNK deficiency decreases obesity-induced
433 insulin resistance via regulation of GLUT4 through the PI3K-Akt-AS160 pathway in adipose tissue.
434 *Aging.* (2020) 12:17150-17166. doi: 10.18632/aging.202421. PMID: 33495419; PMCID:
435 PMC7906173.
- 436 (43) Rumora AE, LoGrasso G, Hayes JM, Mendelson FE, Tabbey MA, Haidar JA, et al. The divergent
437 roles of dietary saturated and monounsaturated fatty acids on nerve function in murine models of
438 obesity. *J Neurosci.* (2019) 39:3770–3781. doi: 10.1523/JNEUROSCI.3173-18.2019

439 **11 Data Availability Statement**

440 The data supporting the findings of this study are available from the corresponding author upon
441 reasonable request. Access to the data will be granted subject to appropriate justification and
442 compliance with relevant ethical and legal requirements.

443 **12 Tables**444 **Table 1. Sociodemographic characteristics (n = 3,501).**

Variable	Mean ± SD	N (%)
Age (years)	67.9 ± 12.94	—
Sex		
Men	—	1,967 (56.2%)
Women	—	1,534 (43.8%)
Country of origin		
Spain	—	2,750 (84.6%)
Other countries	—	499 (15.4%)
Residence		
Urban	—	2,345 (67%)
Rural	—	1,156 (33%)

445 **Table 2. Clinical and biochemical parameters in men, women, and the total population.**

Variable	Total Mean ± SD (N)	Men Mean ± SD (N)	Women Mean ± SD (N)
Glucose (mg/dL)	157.19 ± 53.82 (3,308)	159.98 ± 55.83 (1,865)	153.58 ± 50.90 (1,443)
HbA1c (%)	7.3 ± 1.55 (56 mmol/mol) (2,898)	7.4 ± 1.63 (57 mmol/mol) (1,630)	7.2 ± 1.45 (55 mmol/mol) (1,268)
TC (mg/dL)	191.93 ± 43.73 (3,107)	187.17 ± 44.72 (1,757)	198.12 ± 41.61 (1,350)
LDL-C (mg/dL)	109.49 ± 36.02 (2,728)	107.18 ± 36.40 (1,517)	112.37 ± 35.33 (1,211)
HDL-C (mg/dL)	48.32 ± 12.82 (2,995)	45.47 ± 11.87 (1,697)	52.03 ± 13.08 (1,298)
TG (mg/dL)	175.84 ± 105.59 (3,010)	180.06 ± 117.33 (1,702)	170.35 ± 87.75 (1,308)
BMI (kg/m ²)	31.84 ± 5.35 (827)	31.65 ± 4.98 (471)	32.08 ± 5.81 (356)
SBP (mmHg)	135.29 ± 16.45 (1,299)	136.53 ± 16.68 (716)	134.07 ± 16.08 (583)
DBP (mmHg)	78.70 ± 10.45 (1,276)	79.96 ± 10.75 (700)	77.17 ± 9.88 (576)

446 HbA1c = glycated hemoglobin, TC = total cholesterol, LDL-C = low-density lipoprotein cholesterol, HDL-C = high-density lipoprotein
 447 cholesterol, TG = triglycerides, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure.

448 **Table 3. Lipid profile according to clinically relevant HbA1c categories**

HbA1c category	Total cholesterol (mg/dL) Mean ± SD (N)	LDL-C (mg/dL) Mean ± SD (N)	HDL-C (mg/dL) Mean ± SD (N)	Triglycerides (mg/dL) Mean ± SD (N)
<7.0 %	188.74 ± 41.34 (1,656)	107.68 ± 35.21 (1,531)	50.55 ± 12.70 (1,606)	156.18 ± 86.99 (1,610)
7.0–8.9 %	191.53 ± 43.77 (729)	108.95 ± 36.01 (629)	45.68 ± 12.28 (709)	188.96 ± 104.49 (711)

HbA1c category	Total cholesterol (mg/dL) Mean ± SD	LDL-C (mg/dL) Mean ± SD	HDL-C (mg/dL) Mean ± SD	Triglycerides (mg/dL) Mean ± SD
	(N)	(N)	(N)	(N)
≥9.0%	204.30 ± 47.52 (351)	116.49 ± 37.64 (269)	42.63 ± 11.08 (342)	230.70 ± 139.71 (335)
p-value	<0.001	0,264	<0.001	<0.001


449 Differences across HbA1c categories were tested with one-way ANOVA for total cholesterol, LDL and HDL cholesterol, and the
450 Kruskal–Wallis test for TG.

451 **Table 4. Effect of HbA1c, sex, age, and BMI on lipid parameters: Adjusted multiple linear regression**
452 **results.**

Dependent Variable	R ²	Predictor	B	p
TC	0.106	HbA1c	4.25	<0.001
		Sex	19.76	<0.001
		Age	-0.55	<0.001
		BMI	-0.49	0.119
LDL-C	0.057	HbA1c	1.67	0.080
		Sex	10.47	<0.001
		Age	-0.54	<0.001
		BMI	-0.41	0.139
HDL-C	0.120	HbA1c	-1.40	<0.001
		Sex	6.07	<0.001
		Age	0.06	0.090
		BMI	-0.22	0.018
TG	0.116	HbA1c	15.65	<0.001
		Sex	8.28	0.264
		Age	-1.011	0.001
		BMI	1.535	0.034

453 B = unstandardized coefficient; p-values in bold indicate statistical significance (p < 0.05). Sex coded as 0 = male, 1 = female.

Figure 1.TIF



[07 July 2026]

Reviewer confirmation

To whom it may concern,

We are pleased to confirm that Yenny Yenny acted as a reviewer for the Family Medicine and Primary Care specialty section in Frontiers in Medicine.

Yenny Yenny was selected for this role by peers based on their expertise in the field and has played an important role in our collaborative peer-review process.

Please feel free to contact the editorial office at medicine@frontiersin.org if you have any questions about the reviewer role.

Best regards,

Ying Yao
Journal Specialist



Mengqi Huang
Journal Manager
Frontiers in Medicine

Indexing

<https://www.scimagojr.com/journalsearch.php?q=21100868809&tip=sid&clean=0>

Frontiers in Medicine

Switzerland | Universities and research institutions | Media Ranking

Country

Switzerland



 Scimago
Media Rankings

Subject Area and Category

Medicine

Medicine (miscellaneous)

Publisher

Frontiers Media SA



SJR 2025

0.952

Q1

H-Index

118

Publication type

Journals

ISSN

2296858X

Coverage

2014-2026

Frontiers in Medicine

Q1

Medicine
(miscellaneous)

best quartile

SJR 2025

0.95



powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimago
```